NCT04168528View on ClinicalTrials.gov

Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 5, 2019

Primary Completion Date

December 4, 2024

Study Completion Date

December 4, 2024

Conditions
Malignant Solid TumorBreast CancerMelanoma (Skin)
Interventions
DRUG

68GaNOTA-Anti-MMR-VHH2

Injection of the radiopharmaceutical and PET/CT imaging

Trial Locations (1)

1090

Uz Brussel, Brussels

All Listed Sponsors
collaborator

Kom Op Tegen Kanker

OTHER

lead

Universitair Ziekenhuis Brussel

OTHER

NCT04168528 - Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT | Biotech Hunter | Biotech Hunter